Baltimore Lipid Center / Gregory Pokrywka MD FACP FNLA NCMP
Complex Cholesterol Management and Prevention of Heart Disease and Diabetes.
Advanced Lipoprotein Testing and Arterial Imaging from a recognized National Thought Leader.
see blog below for updates !
Learn more about my exciting new partnership with ModernMed here ! Why ModernMed ? Innovative preventive and concierge medical solutions.
Ultimate facilitator of healthcare services. Uncompromising service experience. Are you ready ? ModernMed is a forward-thinking
health care service firm designed to create a better health care experience for patients, physicians and businesses. We establish
and maintain modern primary care practice environments across the country that are unlike any traditional practice. As a company
focused on exceeding the expectations of its physician, patient and business customers, we maintain primary care environments
that have people looking at health care in a whole new light.
FirstLine Therapy (FLT)®
—therapeutic lifestyle change
(TLC) program to manage, prevent, or reverse chronic diseases
(such as prediabetes, diabetes, cholesterol disorders, obeisty.) Call the office to schedule your own 12 week FLT lifestyle
intervention program. This program will augment or even replace existing medications, and should be covered by
patient insurance (as I am involved in every visit, along with a Board Certified Dietitian.) In the meantime you can
begin ordering MetaGenics nutritional products to reduce your risk for diabetes and cardiovascular disease (or click on
The Baltimore Lipid Center also does CardioMetabolic Risk (diabetes/ coronary artery disease etc. ) consults,
and we can work WITH and report back TO, your regular doctor. This is the ONLY suburban Baltimore Lipid Clinic
(specializing in cholesterol disorders and prevention of heart disease and diabetes) , and we draw advanced cholesterol/ lipoprotein
testing , as well as offering screening for early plaque/ atherosclerosis with in-house Carotid Ultrasound.
Find out why Health Diagnostics Laboratories (www.myhdl.com) offers the most advanced testing for cardiovscualr disease and diabetes (covered/ accepted by ALL insurances.)
Welcome to our new practice website !
Gregory Pokrywka MD FACP FNLA NCMP
Director, Baltimore Lipid Center
ABCL certified Clinical Lipidologist
Aggressive diagnosis and treatment
of lipid (cholesterol and triglyceride) disorders-prevention of heart attack, stroke, and diabetes.
North American Menopause
Society Certified Menopausal Clinician. (Only a handful of US physicians are "double-boarded" in Menopause and Clinical Lipidology)
Professor, Johns Hopkins University School of Medicine
General Internal Medicine
Prevention is the Key !
I practice quality not quantity medicine.
Goals 2012 :
- Establish Preventive Medicine practice and continue consultation services.
- State of the art, efficient, caring, Internal Medicine, Lipidology and Menopausal Medicine.
- Prevention of cardiovascular
disease (heart attack and stroke).
- Nationwide educational
lecturer, author and thought leader in Clinical and Menopausal Lipidology.
Choosing a healthcare provider is one of the most important decisions you can make. You want someone who is
caring, knowledgeable, and accessible. Someone willing to take the time to go over all of your options and treat you as a
person, not just a patient.
At my practice, we pride ourselves on our patient service. We offer a knowledgeable
staff, safe and proven procedures, and the latest in medical technology. Dr. Pokrywka has extensive experience in advanced
cholesterol / lipoprotein testing, and in on-site Carotid IMT ultrasound imaging for atherosclerosis screening, and
utilizing clinical nutrition consultation. I've created this web site for both new and current patients. It includes specific
information on the practice and the staff along with general wellness information.
Monday, March 15, 2010
ACCORD trial validates the use of fenofibrate (Tricor, Trilipix, Lipofen, Antara) for Residual Risk reduction
7:04 am est
ACCORD Lipid Study brings new hope to people with type 2 diabetes and atherogenic
Prof. JC Fruchart, Prof. F Sacks, Prof. M Hermans From the 59th Scientific Sessions of the American College
Board of the R3i
14th March 2010
For the last two years the Residual Risk Reduction Initiative
(R3i) has supported the hypothesis of residual vascular risk and its clinical importance. This is encapsulated in the position
papers published by the Foundation during this time.
Now, we are delighted that the long-anticipated announcement of
the results from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial confirms that, targeting non-LDL lipids
in a sub-group of statin-treated diabetic patients with well-controlled low-density lipoprotein cholesterol (LDL-C), reduces
cardiovascular events and is consistent with the position taken by the R3i.1
ACCORD Lipid also shows that in this sub-group
analysis, pre-specified in the study protocol, this high residual risk can be substantially reduced with the addition of fenofibrate.
A reduction of 31 percent in cardiovascular risk in patients with type 2 diabetes and atherogenic dyslipidemia who had reached
LDL-C goals was achieved when compared to patients taking simvastatin alone. This reduction is comparable in magnitude
to those seen in landmark statin trials.
The benefit of fenofibrate was only seen in the group of patients with atherogenic
dyslipidemia, and none of the primary or secondary endpoints were statistically significant in the total study population
which included many patients with LDL-C at goal and without combined atherogenic dyslipidemia. There is a risk that the positive
and clinically important results seen in ACCORD Lipid will be lost in the context of ACCORD being seen as a ‘negative’ study.
This puts the R3i in a unique and very important position. We have to ensure that the clinical implications of this
very important study are not misinterpreted and that the millions of diabetic patients with atherogenic dyslipidemia can benefit
from a further reduction in CVD morbidity and mortality. Given the magnitude of the global epidemic of type 2 diabetes – especially
in developing regions – a lipid-modifying strategy that combines fenofibrate with a statin could play an important role in
reducing the global burden of residual vascular risk in type 2 diabetic patients with atherogenic dyslipidemia, who represent
a huge population on a global scale.
This unique evidence from ACCORD will support our existing research activities.
Indeed, the REALIST study, being conducted at Harvard Medical School and over 20 well-known academic centers worldwide, becomes
even more important. The REALIST will form the platform for the R3i’s activities at the European Society of Cardiology.
shows that residual vascular risk can be safely and effectively addressed in patients with type 2 diabetes and atherogenic
dyslipidemia. It is up to all of us to ensure that this message is communicated as effectively as possible to fellow physicians
across the world as soon as possible.
1. The ACCORD Study Group. Effects of combination
lipid therapy in type 2 diabetes mellitus. N Eng JMed 2010. DOI:10.1056/NEJMoa1001282
Baltimore Lipid Center
Gregory Pokrywka MD
7801 York Road #300
Towson, Maryland 21204-7449
NON-URGENT matters, please contact us via email at :
Monday 11:30 am - 8 pm
Tuesday 11:30 am - 6 pm
Wed-Friday 7:30 am - 3:30 pm
(hours may occ. vary due to Dr. Pokrywka's national lecturing